Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Sep 2008 - Int. J. Oncol.; 33(4):1019-6439 [PMID:18813797] [Janke M] [Peeters B] [Zhao H] [de Leeuw O] [Moorman R] [Arnold A] [Ziouta Y] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Jul 2008 - Virus Res.; 136(1-2):0168-1702 [PMID:18538434] [Zhao H] [Janke M] [Fournier P] [Schirrmacher V]
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Mrz 2008 - Int. J. Oncol.; 32(4):1019-6439 [PMID:18360705] [Aigner M] [Janke M] [Lulei M] [Beckhove P] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Nov 2007 - Gene Ther.; 14(23):0969-7128 [PMID:17914407] [Janke M] [Peeters B] [de Leeuw O] [Moorman R] [Arnold A] [Fournier P] [Schirrmacher V]
